Jason Kolbert

Vernon Bernardino

Peter Levine

Ralph Martini

- Can-Fite BioPharma Ltd. will hold a Special General Meeting of Shareholders on **November 3, 2025**, at 3:00 p.m. Israel time.  **[1536196_0001213900-25-096097_ea0259220-6k_canfite.htm:0]** **[1536196_0001213900-25-096097_ea025922001ex99-1_canfite.htm:0]** 
- Shareholders will vote on a proposal to **increase the Company's authorized share capital by 22,000,000,000 ordinary shares**, resulting in a total authorized share capital of **42,000,000,000 ordinary shares**.  **[1536196_0001213900-25-096097_ea025922001ex99-1_canfite.htm:0]** **[1536196_0001213900-25-096097_ea025922001ex99-1_canfite.htm:4]** 
- A second proposal is to approve a **reverse split of the Company's ordinary shares** at a ratio of **one (1) ordinary share for three thousand (3,000) ordinary shares**.  **[1536196_0001213900-25-096097_ea025922001ex99-1_canfite.htm:0]** **[1536196_0001213900-25-096097_ea025922001ex99-1_canfite.htm:5]**  This is recommended due to a decline in share price to make shares more attractive to investors.  **[1536196_0001213900-25-096097_ea025922001ex99-1_canfite.htm:5]** 
- The Board of Directors **unanimously recommends a vote "FOR" each of the proposals**.  **[1536196_0001213900-25-096097_ea025922001ex99-1_canfite.htm:1]** **[1536196_0001213900-25-096097_ea025922001ex99-1_canfite.htm:5]** **[1536196_0001213900-25-096097_ea025922001ex99-1_canfite.htm:6]**

Can-Fite BioPharma Ltd. to Hold Special General Meeting for Capital Increase and Reverse Stock Split

- Can-Fite BioPharma Ltd. announced the **complete resolution of esophageal varices** in a decompensated cirrhosis patient treated with **Namodenoson** under a compassionate use program.  **[1536196_0001213900-25-087400_ea025678401ex99-1_canfite.htm:0]** 
- This clinical finding, confirmed by endoscopic evaluation, is an **uncommon clinical outcome** and may suggest a **disease-modifying effect** of Namodenoson for advanced liver disease.  **[1536196_0001213900-25-087400_ea025678401ex99-1_canfite.htm:0]** 
- Namodenoson is currently being evaluated in a **Phase III clinical trial** for hepatocellular carcinoma (HCC), a **Phase IIb trial** for Metabolic Dysfunction-associated Steatohepatitis (MASH), and a **Phase IIa study** in pancreatic cancer.  **[1536196_0001213900-25-087400_ea025678401ex99-1_canfite.htm:0]** **[1536196_0001213900-25-087400_ea025678401ex99-1_canfite.htm:1]** 
- The U.S. market for liver cirrhosis treatment is projected to grow to approximately **$15 billion by 2030**, underscoring the urgent need for new therapies.  **[1536196_0001213900-25-087400_ea025678401ex99-1_canfite.htm:0]**

Can-Fite BioPharma Reports Complete Resolution of Esophageal Varices with Namodenoson

- Can-Fite BioPharma Ltd. reported a **net loss of $4.87 million** for the six months ended June 30, 2025, an increase from a net loss of $3.95 million in the prior year period. Revenues for the same period decreased by **36.07%** to **$0.20 million**.  **[1536196_0001213900-25-081407_ea025460601ex99-2_canfite.htm:0]** **[1536196_0001213900-25-081407_ea025460601ex99-3_canfite.htm:1]** **[1536196_0001213900-25-081407_ea025460601ex99-1_canfite.htm:4]** 
- As of June 30, 2025, the company had **$6.45 million** in cash and cash equivalents and short-term deposits.  **[1536196_0001213900-25-081407_ea025460601ex99-3_canfite.htm:1]** **[1536196_0001213900-25-081407_ea025460601ex99-1_canfite.htm:4]**  Subsequent to this date, in July 2025, Can-Fite completed a public offering, raising **$5 million** in gross proceeds.  **[1536196_0001213900-25-081407_ea025460601ex99-3_canfite.htm:1]** **[1536196_0001213900-25-081407_ea025460601ex99-2_canfite.htm:2]** **[1536196_0001213900-25-081407_ea025460601ex99-1_canfite.htm:3]** **[1536196_0001213900-25-081407_ea025460601ex99-2_canfite.htm:8]** 
- The company's Namodenoson drug candidate achieved **over 50% enrollment** in its Phase 2a pancreatic cancer study and received **Orphan Drug Designation** from the U.S. FDA for this indication.  **[1536196_0001213900-25-081407_ea025460601ex99-3_canfite.htm:0]**  Additionally, Piclidenoson demonstrated potential as a treatment for vascular dementia in a study by UCLA.  **[1536196_0001213900-25-081407_ea025460601ex99-3_canfite.htm:0]** 
- Can-Fite's history of net losses and operating cash outflows raise substantial doubt about its ability to continue as a going concern, though management expects existing financial resources to be sufficient for at least the next twelve months and plans to reduce non-essential expenses and defer certain R&D programs.  **[1536196_0001213900-25-081407_ea025460601ex99-2_canfite.htm:2]** **[1536196_0001213900-25-081407_ea025460601ex99-1_canfite.htm:5]**

Can-Fite BioPharma (CANF)